Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2018-0016
Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2019-0005
Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2018-0013
Identifying successful biomarkers for patients with non-small-cell lung cancer
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2019-0009
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2019-0001
Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2019-0004
Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2018-0010
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2018-0017
We need to educate young lung cancer patients about menopause risk
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2018-0018
Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2019-0003
Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods
来源期刊:Lung Cancer ManagementDOI:10.2217/lmt-2019-0006